These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29699358)

  • 1. A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn's Disease.
    Goral V; Unsal B; Nermin Sivrikoz O
    Euroasian J Hepatogastroenterol; 2014; 4(2):104-106. PubMed ID: 29699358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
    Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
    Panaccione R;
    Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O; Blumenstein I; Stein J
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
    Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome.
    Morita K; Shibano T; Maekawa K; Hattori M; Hida N; Nakamura S; Takeshima Y
    CEN Case Rep; 2019 Feb; 8(1):55-60. PubMed ID: 30251194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL
    Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease.
    Thurlapati A; Gandu SSK; Kulkarni S
    Cureus; 2021 Jun; 13(6):e15835. PubMed ID: 34327073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.